Finally, although molecular testing has mostly had treatment impacts in the metastatic setting, with the approval of osimertinib for adjuvant treatment in EGFR-mutant resected NSCLC, it is now important to expand this testing into early stages to capture these patients who harbor mutations to be able to provide matched therapy.41 Further study will be needed to determine the potential economic impact of SGT versus expanded NGS testing into earlier-stage lung cancers and the cost-effectiveness of ADO-targeted therapies in this setting. The gene discussed is EGFR; the disease is lung cancer.